NCT06964061View on ClinicalTrials.gov

Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2026

Conditions
Open Angle Glaucoma (OAG)Ocular Hypertension (OH)
Interventions
COMBINATION_PRODUCT

PA5436 Ocular Implant, 115mcg

The PA5346 Ocular Implant is supplied preloaded into the needle of a single use Administration Device ready for use.

Trial Locations (2)

3000

RECRUITING

Melbourne Eye Specialists, Melbourne

3109

RECRUITING

Cataract & Eye Surgery Centre, Doncaster

Sponsors

Lead Sponsor

PolyActiva Pty Ltd
All Listed Sponsors
lead

PolyActiva Pty Ltd

INDUSTRY

NCT06964061 - Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter